Business
Block listing Interim Review
AstraZeneca PLC has reported its six-month return for block listings covering the period from June 1, 2025, to November 30, 2025, indicating a decrease in unallotted securities. The company began this period with 3,688,383 unallotted securities across its various share option and savings-related share plans. During this reporting period, 67,907 securities were issued or allotted under these schemes, resulting in a closing balance of 3,620,476 unallotted securities. The block scheme itself was not increased during this period. Disclaimer*
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n1 December 2025\n \n \nBLOCK LISTING SIX MONTHLY RETURN\n \nInformation provided on this form must be typed or printed electronically and provided to a PIP.\n \n(Note: Italicised terms have the same meaning as given in the Listing Rules.)\n \nDate: 1 December 2025\n \n\n\n\n\nName of applicant:\n\n\nASTRAZENECA PLC\n\n\n\n\nName of scheme:\n\n\nASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME\n\n\n\n\nPeriod of return:\n\n\nFrom:\n\n\n1 JUNE 2025\n\n\nTo:\n\n\n30 NOVEMBER 2025\n\n\n\n\nBalance of unallotted securities under scheme(s) from previous return:\n\n\n3,688,383\n\n\n\n\nPlus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\n\n\n0\n\n\n\n\nLess: Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G):\n\n\n67,907\n\n\n\n\nEquals: Balance under scheme(s) not yet issued/allotted at end of period:\n\n\n3,620,476\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\nName of contact:\n\n\nHannah Tattersall\n\n\n\n\nTelephone number of contact:\n\n\n+44 (0)20 3749 5000\n\n\n\n\n \n \nAstraZeneca \nAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca \n \n \nContacts\nFor details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.\n \n \nMatthew Bowden\nCompany Secretary\nAstraZeneca PLC\n \n\n","length":7214,"tagName":"div"}]